Merck Serono Research Hub Beijing

 
October 2011- Merck Serono newest R&D hub established in November 2009 in the Beijing area, expanded in 2011 through a strategic partnership with Pharmaron, opening an R&D laboratory on the Pharmaron campus.

The Beijing hub leads drug development for local clinical trials and participation in global clinical trials. Merck Serono's presence enables to liaise more effectively with regulatory officials, academic institutions and other research-oriented organizations as well as conduct clinical trials that accelerate the development of products to treat high-prevalence diseases in China. There is a continuous effort to look for partnerships with local academic institutions and companies.

Research activities at the Beijing R&D hub focus mainly on biomarker research, including pharmacogenomics and bioanalytics, which is part of our stratified medicine approach. The development of Merck serono's activities are centered on Oncology, Neurodegenerative Diseases and Rheumatology. The expertise is concentrated in clinical monitoring, clinical trial management, data management, biostatistics, statistical programming, clinical development units, regulatory affairs, non-clinical development, portfolio and project management, quality assurance, drug safety and medical affairs.

Merck Serono (Beijing) Pharmaceutical R&D Co., Ltd.
The R&D Beijing Hub is an integrated R&D facility, aimed at stimulating innovation, introducing new products to Asia paralleling market timelines in the West, and leading research and development into new treatment solutions for critical diseases in Asia.

CONTACT
Merck Serono (Beijing) Pharmaceutical R&D Co., Ltd.
10F, Tower B, Gemdal Plaza,
No.91 Jianguo Road,
Chaoyang District,
100022 Beijing,
P.R. China

BioWin signs an agreement with Juke Biotech Park (Shanghai)

October 2011-

BioWin, the Health competitiveness cluster of Wallonia (Belgium), has announced that a partnership agreement was signed on the 14th of October of this year with Juke Biotech Park, a new public funded Science Park in Shanghai (China) that hosts more than a hundred Chinese SMEs and research centres specialised in health biotechnologies and medical technologies. Under the agreement, an operational infrastructure and facilities will be provided to Laurent Le Guyader, BioWin’s permanent representative in Shanghai as International Relations Manager – China. Mr Le Guyader reports to Yve van Thorenburg, International Relations Manager – Asia and Frédéric Druck, who heads the BioWin international unit. Juke Biotech Park has further undertaken to smooth the way for access to the Chinese market to BioWin members. And vice versa, BioWin will ease as much as possible the access of Juke Biotech Park companies to Wallonia as strategic gate to the European market. This agreement is the fruit of a strategy to develop the BioWin activities in China, first launched in 2009. It was signed in the course of a recent BioWin and AWEX (Walloon Export and Foreign Investment Agency) mission to the Bio China trade fair 2011. BioWin was eager to conclude this agreement to keep step with the growing interest for the Chinese market expressed by Walloon SMEs and research centres working in the field of health biotechnologies and medical technologies. This is the second agreement concluded with a preferred partner on location in Shanghai, the Chinese city that has become an indispensable hub when it comes to healthcare innovation. *** Press contacts: Frédéric Druck – BioWin Head of Communication and International Relations Tel. +32 (0)474/52.02.69 - frederic.druck@biowin.org